Budesonide: a new corticosteroid in bronchial asthma

Area of Science:

• Pharmacology
• Respiratory Medicine
• Clinical Investigation

Background:

• Chronic bronchial asthma requires effective treatment options.
• Glucocorticoids are a cornerstone therapy for asthma management.
• Budesonide is a non-halogenated glucocorticoid with anti-inflammatory properties.

Purpose of the Study:

• To compare the time course of response to inhaled budesonide, oral budesonide, and oral prednisolone in asthma patients.
• To evaluate the efficacy of different administration routes of budesonide.
• To assess the impact on Peak Expiratory Flow (PEF).

Main Methods:

• 12 patients with chronic bronchial asthma participated.
• Administered budesonide 1000 mcg via inhalation.
• Administered budesonide 800 mcg orally.
• Administered prednisolone 40 mcg orally.
• Measured Peak Expiratory Flow (PEF) over time.

Main Results:

• Inhaled budesonide and oral prednisolone significantly increased PEF within 2 hours.
• Peak effect for inhaled budesonide occurred 6-7 hours post-administration.
• Peak effect for oral prednisolone occurred around 9 hours post-administration.
• Oral budesonide did not produce substantial changes in PEF.

Conclusions:

• Inhaled budesonide demonstrates a rapid and significant bronchodilatory effect in asthma patients.
• Oral budesonide is less effective than inhaled budesonide or oral prednisolone for improving PEF.
• Inhalation is the preferred route for budesonide administration in managing asthma symptoms.